23:27 , Jul 15, 2019 |  BC Extra  |  Financial News

AI play Recursion raises $121M to expand into new drug discovery

Recursion’s $121 million series C round will allow the company to expand its artificial intelligence-based drug repurposing platform for rare diseases and develop capabilities for new drug discovery while pushing its pair of lead programs...
21:52 , May 30, 2019 |  BC Extra  |  Financial News

May 30 Financial Quick Takes: $200M series F for Tempus; plus TFF, Frontage Holdings

Tempus raises $200M for precision medicine platform  Bringing its valuation to $3.1 billion, Tempus Labs Inc. (Chicago, Ill.) raised $200 million in a series F round to expand its precision medicine platform into new therapeutic...
20:49 , May 24, 2019 |  BioCentury  |  Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
22:24 , Dec 20, 2018 |  BC Innovations  |  Emerging Company Profile

KSQ: Widescreen CRISPR

KSQ Therapeutics Inc. is developing therapies using its CRISPRomics technology to identify cancer and immuno-oncology targets by screening all human genes in cancer cell lines and T cells. The company emerged from stealth in 2017...
23:07 , Oct 11, 2018 |  BC Week In Review  |  Financial News

Gene therapy developer Orchard proposes IPO

Orchard Therapeutics Ltd. (London, U.K.) proposed to raise up to $172.5 million in an IPO on NASDAQ. J.P. Morgan, Goldman Sachs, Cowen and Wedbush PacGrow are underwriters. Orchard is developing autologous ex vivo lentiviral gene...
13:08 , Oct 5, 2018 |  BC Extra  |  Financial News

Gene therapy developer Orchard proposes IPO

Orchard Therapeutics Ltd. (London, U.K.) proposed to raise up to $172.5 million in an IPO on NASDAQ. J.P. Morgan, Goldman Sachs, Cowen and Wedbush PacGrow are underwriters. Orchard is developing autologous ex vivo lentiviral gene...
10:01 , Sep 28, 2018 |  BC Extra  |  Financial News

Flagship leads $80M round for immunotherapy play KSQ

KSQ Therapeutics Inc. (Cambridge, Mass.) plans to use the proceeds from an $80 million series C round to advance its first program -- a modified adoptive T cell immunotherapy -- into the clinic within the...
18:26 , Aug 31, 2018 |  BC Week In Review  |  Financial News

Tempus raises $110M series E

Tempus Labs Inc. (Chicago, Ill.) raised $110 million on Aug. 29 in a series E round led by new investor Baillie Gifford and funds managed by T. Rowe Price. Existing investors Revolution Growth, New Enterprise...
17:15 , Aug 29, 2018 |  BC Extra  |  Financial News

Tempus raises $110M series E

Tempus Labs Inc. (Chicago, Ill.) raised $110 million in a series E round led by new investor Baillie Gifford and funds managed by T. Rowe Price. Existing investors Revolution Growth, New Enterprise Associates and other...
17:25 , Aug 17, 2018 |  BC Week In Review  |  Financial News

Crossover investors join Orchard's syndicate in $150M series C

Gene therapy company Orchard Therapeutics Ltd. (London, U.K.) raised $150 million on Aug. 13 in a series C round led by Deerfield Management. Also participating were new investors RA Capital, Venrock, Foresite Capital, Perceptive Advisors,...